Introduction : While the number of women physicians is increasing in Japan, there is a tendency for these physicians to leave the workforce during their child-rearing years, contributing to an overall physician shortage. In order to create effective policies to ameliorate these shortages, it is important to assess women medical students' views on their careers after marriage and the factors that lead to a low motivation for continuation of their careers..
Methods : From 2010 to 2012, we conducted questionnaire surveys using visual analog scale (VAS) based and multiple choice questions on medical students at the University of Tokushima regarding these issues in women physicians. We analyzed the results of questions included in each of these three-year surveys for women medical students in the first, third and sixth year and men in their sixth year..
Results : VAS results for “intention to continue career after marriage” showed shorter measurements in sixth year women (median 86.5mm, interquartile range (IQR) 64-97mm) compared to sixth year men (median 98mm, IQR 92.5-100mm) (p<0.001). Sixth year women with a VAS of 75mm or under for “intention to continue career” showed less “interest in a medical career” than those with a VAS of 80mm or greater (median 79.5mm (IQR 64.5-88.5) vs. 90.5mm (IQR 82-100)) (p=0.001). All student groups analyzed indicated that a “sense of purpose” was the most important factor in their future careers.
Conclusion : Lower VAS levels for “the intention to continue career after marriage” were related to a lower level for “interest in a medical career” in women medical students, which has implications for education and guidance in the undergraduate years.

BACKGROUND/AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE Induction were re-randomized to 52 weeks' therapy with placebo, tofacitinib 5 mg BID, or tofacitinib 10 mg BID. METHODS: We conducted post-hoc efficacy and safety analyses of East Asian patients in OCTAVE Induction 1 and 2 and OCTAVE Sustain. RESULTS: A total of 121 East Asian (Japan, Korea, and Taiwan) patients were randomized in OCTAVE Induction 1 and 2 (placebo, n=26; tofacitinib 10 mg BID, n=95), and 63 in OCTAVE Sustain (placebo, n=20; tofacitinib 5 mg BID, n=22; tofacitinib 10 mg BID, n=21). At week 8 of OCTAVE Induction 1 and 2, 18.9% of patients (18/95) achieved remission with tofacitinib 10 mg BID versus 3.8% (1/26) with placebo. In OCTAVE Sustain, the week 52 remission rates were 45.5% (10/22), 47.6% (10/21), and 15.0% (3/20) with 5 mg BID, 10 mg BID, and placebo, respectively. Adverse event rates were similar between groups in OCTAVE Induction and numerically higher with tofacitinib in OCTAVE Sustain. Serious adverse event rates were similar across groups in all studies. Infections were numerically more frequent with tofacitinib than placebo. Increases in serum lipid levels were observed with tofacitinib. CONCLUSIONS: In East Asian patients with UC, tofacitinib demonstrated numerically greater efficacy versus placebo as induction and maintenance therapy, with a safety profile consistent with the global study population. ClinicalTrials.gov: NCT01465763; NCT01458951; NCT01458574.
Asian Continental Ancestry Group* ; Colitis, Ulcerative* ; Humans ; Korea ; Phosphotransferases ; Ulcer*

The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being presented in the publication. The error does not affect the overall conclusions regarding IBDQ as the difference between the corrected and erroneous numbers is, in general, small. The error was specific to IBDQ data; all other data have been reviewed and are correct as originally reported.
Asian Continental Ancestry Group* ; Colitis, Ulcerative* ; Humans ; Inflammatory Bowel Diseases ; Publications ; Ulcer*